SCHEMBL9608985

SCHEMBL9608985

CCc1c(Cl)ccc(C)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
PKM P14618 1/20 0.32
TAAR1 Q96RJ0 1/20 0.31
NOS3 P29474 1/20 0.31
NOS2 P35228 1/20 0.31
CYP3A4 P08684 1/20 0.31
RORC P51449 1/20 0.31
S1PR1 P21453 1/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
BRD9 Q9H8M2 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
RAPGEF4 Q8WZA2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16941876 0.84 TAAR1 (0.34) HTR2AHTR2CHTR2BPKMTAAR1
SCHEMBL26448358 0.83 HTR2A (0.37) P2RX7HTR2AHTR2CHTR2BPKM
SCHEMBL11891674 0.81 NOS3 (0.40) HTR2AHTR2CHTR2BNOS3NOS2
SCHEMBL1168411 0.81 P2RX7 (0.43) P2RX7HTR2AHTR2CHTR2BPKM
SCHEMBL3591836 0.81 HTR2A (0.46) P2RX7HTR2AHTR2CHTR2BPKM
SCHEMBL955817 0.81 HTR2A (0.42) P2RX7HTR2AHTR2CHTR2BPKM
SCHEMBL23378582 0.80 TAAR1 (0.36) PKMTAAR1PTGS1PTGS2BRD9
SCHEMBL3871164 0.78 TAAR1 (0.35) HTR2AHTR2CHTR2BTAAR1NOS3
SCHEMBL16939399 0.78 P2RX7 (0.38) P2RX7HTR2AHTR2CHTR2BRORC
SCHEMBL14613817 0.78 P2RX7 (0.41) P2RX7HTR2AHTR2CHTR2BCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9695166-B2 Pyrazolopyridine pyrazolopyrimidine and related compounds GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-07-04 US disclosed
US-9556168-B2 N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof MERCK SHARP & DOHME CORP. (US) 2017-01-31 US disclosed
US-20150315198-A1 PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2015-11-05 US disclosed
US-20150210687-A1 N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC 2015-07-30 US disclosed
US-20120135975-A1 Substituted Esters as Cannabinoid-1 Receptor Modulators MERCK & CO., INC. (US) 2012-05-31 US disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 US disclosed
US-7279484-B2 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease AJINOMOTO CO., INC. (JP) 2007-10-09 US disclosed
US-7279484-B2 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease AJINOMOTO CO., INC. (JP) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312435-A1 Imine Compound CNR1, CNR2, HRH4 P2RX7 225/4885HTR2A 257/4885HTR2C 124/4885
US-20150210687-A1 N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF RORB, RORC, RORA P2RX7 1640/4885HTR2A 1152/4885HTR2C 824/4885
US-20150315198-A1 PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS TPMT, DPYD, XDH P2RX7 65/4885HTR2A 3450/4885HTR2C 1952/4885
US-20120135975-A1 Substituted Esters as Cannabinoid-1 Receptor Modulators CNR1, CNR2, FAAH P2RX7 1478/4885HTR2A 550/4885HTR2C 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.